Objectives: To describe: the pattern of anti-ENA positive tests; frequency of repeated requests; stability and repeatability of anti-Jo-1 tests; clinical characteristics of anti-Jo-1 +ves compared with controls; and diagnostic value of anti-Jo-1 for ILD. Methods: All anti-ENA test requests, from any hospital department, between Jan 2013 and Dec 2014 were identified. Serum samples are screened for ENA (Quanta Lite ® ENA profile, Inova Diagnostics) and positive samples have specific ENA antibodies levels quantified. Data from anti-Jo-1 positive patients and controls was extracted from electronic records allowing a minimum of 12 months after first test. Results:
4009 samples from 3581 patients were tested. The first sample tested, chronologically, was designated test of interest. 616 (17.2%) patients were anti-ENA screen +ve, and 40 (1.1%) anti-Jo-1 +ve (>20 AU/mL). Anti-ENA tests were done more than once for 350/3581 (9.8%) patients (428/4009 (10.7%) samples) and for 7/40 (17.5%) of anti-Jo-1 +ve patients. The median interval between 1st and 2nd requests: 124 days (IQR 233 days). The Table shows data for anti-Jo-1 patients and randomly selected ENA -ve controls. The frequency of ILD, myositis and Raynaud's was comparable. Sensitivity and specificity of Jo-1 for ILD, a key feature of "anti-synthetase syndrome", were 50% (CI 19-81%) and 68% (CI 59-77%) respectively. Positive predictive value 12.5% (CI 4 to 27%) and negative predictive value 93.8% (CI 86-98%). Of patients with the highest anti-Jo1 titres (≥40 AU/mL, 10/40 patients, 25%): 3 had ILD, 1 myositis and 2 had a malignancy (disseminated melanoma and CML). Bland-Altman plots show that anti-Jo-1 values remained stable when patients were re-tested at another time but re-testing available stored samples from +ve patients showed important variation ( Figure) .
Conclusions: Anti-Jo-1 is uncommon in a heterogenous hospital population and is only weakly predictive for ILD. Background: In rheumatoid arthritis (RA), patients in low activity disease or clinical remission measured by disease activity indexs can present subclinical activity by ultrasound study. The ultrasonographic inflammation in examination of joints is an important predictive value of structural damage. Objectives: The aim of our study was to describe subclinical ultrasonographics activity in patients with RA in low disease activity or clinical remission, with optimized biological therapy and non biological treatment. Methods: Transversal and longitudinal study describing the ultrasonographic changes in gray scale and doppler in parallel with blind clinical evaluation. We included patients with RA according to ACR/EULAR classification criteria in low activity disease or remission measured by DAS28, under optimized biological therapy at least for 6 months and non biological treatment. They were sent by their usual clinician, making a random selection. They were evaluated in the same day by a rheumatologist and blind sonographer. VAS, VGP, VGM, HAQ, tender joints count, swollen joint count, CDAI, SDAI and DAS28 were evaluated. Regarding the ultrasound, were evaluated synovitis and doppler in 12 joints (wrists, second to fifth MCF and fifth bilateral MTF). The comparison between clinical examination and ultrasonography test was performed by the kappa index, with satisfactory value of >0,6. Results: A total of 69 patients were included, 35 with optimized biological therapy and 34 non biological treatment. The median optimization time was 12 months. The baseline characteristics only offered stadistical significance in swollen joint count and average time of disease (table 1). The concordance study between clinical joint exploration and ultrasonographic examination showed a higher kappa index in patients with optimized biological therapy: 0,52 in gray scale and 0,40 in doppler. In patients without biological therapy showed an index kappa =0.17 by the gray scale test, and kappa index =0.26 by doppler. 
Conclusions:
We found no specific ultrasonographic feature specific for HCV related knee arthritis, the knee effusion is a predominant feature and the hypertrophied synovium is not frequently found. No destructive lesions were found to be related to the disease itself; however this should be confirmed by histopathological assessment. Objectives: The aim of this study was to systematically summarize the criteria available to classify or diagnose DISH to aid in the development of a more uniform set of diagnostic and/or classification criteria. Methods: A search was performed in Pubmed, Embase, Cochrane Library and Web of Science using the term DISH and its synonyms. Articles were included when two independent observers agreed that the articles proposed a new set of classification criteria for DISH. All retrieved articles were evaluated for methodological quality and the presented criteria were extracted. The criteria were placed into one of three groups being "descriptive studies", "sets of criteria for dichotomous diagnosis" or "sets of criteria with consecutive phases". Results: A total of 24 articles met the inclusion criteria. Two articles were descriptive studies, 11 contained dichotomous classification criteria and 11 described a set of criteria with consecutive phases. In all articles spinal hyperostosis was required for the diagnosis of DISH. Peripheral, extraspinal manifestations were included as a (co-)requirement for the diagnosis DISH in five articles. Most discrepancies revolved around the threshold for the number of vertebral bodies affected and to defining different developmental phases of DISH. More than half of the retrieved articles described a dichotomous set of criteria and did not consider the progressive character of DISH. Conclusions: In our systematic review we summarize the available different classification criteria for DISH and highlight the lack of consensus on the diagnosis of (early) DISH. Consensus criteria, including consecutive phases of new bone formation that characterize DISH can be developed based upon established diagnostic and/or classification criteria. 
